General MedicationsORALStandard
LIFYORLITM
RELACORILANT
Standard Dose
150MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary
Approval overview LIFYORLITM is listed in Drugs@FDA under application 220641 (NDA).
Review priority: STANDARD Marketing status: Prescription Active ingredient RELACORILANT Form and strength CAPSULE; ORAL - 150MG Sponsor CORCEPT THERAP Submission history Latest submission status date: 2026-03-25 00:00:00.
Structured Monograph
Clinical summary
Approval overview LIFYORLITM is listed in Drugs@FDA under application 220641 (NDA). Review priority: STANDARD Marketing status: Prescription Active ingredient RELACORILANT Form and strength CAPSULE; ORAL - 150MG Sponsor CORCEPT THERAP Submission history Latest submission status date: 2026-03-25 00:00:00. Submission type: ORIG.
Monitoring
- • Marketing status: Prescription
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.